Pretreatment and early-treatment cortical thickness is associated with SSRI treatment response in major depressive disorder

Elizabeth A. Bartlett, Christine DeLorenzo, Priya Sharma, Jie Yang, Mengru Zhang, Eva Petkova, Myrna Weissman, Patrick J. McGrath, Maurizio Fava, R. Todd Ogden, Benji T. Kurian, Ashley Malchow, Crystal M. Cooper, Joseph M. Trombello, Melvin McInnis, Phillip Adams, Maria A. Oquendo, Diego A. Pizzagalli, Madhukar Trivedi, Ramin V. Parsey

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

To date, there are no biomarkers for major depressive disorder (MDD) treatment response in clinical use. Such biomarkers could allow for individualized treatment selection, reducing time spent on ineffective treatments and the burden of MDD. In search of such a biomarker, multisite pretreatment and early-treatment (1 week into treatment) structural magnetic resonance (MR) images were acquired from 184 patients with MDD randomized to an 8-week trial of the selective serotonin reuptake inhibitor (SSRI) sertraline or placebo. This study represents a large, multisite, placebo-controlled effort to examine the association between pretreatment differences or early-treatment changes in cortical thickness and treatment-specific outcomes. For standardization, a novel, robust site harmonization procedure was applied to structural measures in a priori regions (rostral and caudal anterior cingulate, lateral orbitofrontal, rostral middle frontal, and hippocampus), chosen based on previously published reports. Pretreatment cortical thickness or volume did not significantly associate with SSRI response. Thickening of the rostral anterior cingulate cortex in the first week of treatment was associated with better 8-week responses to SSRI (p = 0.010). These findings indicate that frontal lobe structural alterations in the first week of treatment may be associated with long-term treatment efficacy. While these associational findings may help to elucidate the specific neural targets of SSRIs, the predictive accuracy of pretreatment or early-treatment structural alterations in classifying treatment remitters from nonremitters was limited to 63.9%. Therefore, in this large sample of adults with MDD, structural MR imaging measures were not found to be clinically translatable biomarkers of treatment response to SSRI or placebo.

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalNeuropsychopharmacology
DOIs
StateAccepted/In press - Jun 19 2018

Fingerprint

Major Depressive Disorder
Serotonin Uptake Inhibitors
Biomarkers
Therapeutics
Gyrus Cinguli
Placebos
Sertraline
Frontal Lobe
Hippocampus
Magnetic Resonance Spectroscopy
Magnetic Resonance Imaging

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health

Cite this

Bartlett, E. A., DeLorenzo, C., Sharma, P., Yang, J., Zhang, M., Petkova, E., ... Parsey, R. V. (Accepted/In press). Pretreatment and early-treatment cortical thickness is associated with SSRI treatment response in major depressive disorder. Neuropsychopharmacology, 1-10. https://doi.org/10.1038/s41386-018-0122-9

Pretreatment and early-treatment cortical thickness is associated with SSRI treatment response in major depressive disorder. / Bartlett, Elizabeth A.; DeLorenzo, Christine; Sharma, Priya; Yang, Jie; Zhang, Mengru; Petkova, Eva; Weissman, Myrna; McGrath, Patrick J.; Fava, Maurizio; Ogden, R. Todd; Kurian, Benji T.; Malchow, Ashley; Cooper, Crystal M.; Trombello, Joseph M.; McInnis, Melvin; Adams, Phillip; Oquendo, Maria A.; Pizzagalli, Diego A.; Trivedi, Madhukar; Parsey, Ramin V.

In: Neuropsychopharmacology, 19.06.2018, p. 1-10.

Research output: Contribution to journalArticle

Bartlett, EA, DeLorenzo, C, Sharma, P, Yang, J, Zhang, M, Petkova, E, Weissman, M, McGrath, PJ, Fava, M, Ogden, RT, Kurian, BT, Malchow, A, Cooper, CM, Trombello, JM, McInnis, M, Adams, P, Oquendo, MA, Pizzagalli, DA, Trivedi, M & Parsey, RV 2018, 'Pretreatment and early-treatment cortical thickness is associated with SSRI treatment response in major depressive disorder', Neuropsychopharmacology, pp. 1-10. https://doi.org/10.1038/s41386-018-0122-9
Bartlett, Elizabeth A. ; DeLorenzo, Christine ; Sharma, Priya ; Yang, Jie ; Zhang, Mengru ; Petkova, Eva ; Weissman, Myrna ; McGrath, Patrick J. ; Fava, Maurizio ; Ogden, R. Todd ; Kurian, Benji T. ; Malchow, Ashley ; Cooper, Crystal M. ; Trombello, Joseph M. ; McInnis, Melvin ; Adams, Phillip ; Oquendo, Maria A. ; Pizzagalli, Diego A. ; Trivedi, Madhukar ; Parsey, Ramin V. / Pretreatment and early-treatment cortical thickness is associated with SSRI treatment response in major depressive disorder. In: Neuropsychopharmacology. 2018 ; pp. 1-10.
@article{6e90fe74b3a74110a9958b26815fb320,
title = "Pretreatment and early-treatment cortical thickness is associated with SSRI treatment response in major depressive disorder",
abstract = "To date, there are no biomarkers for major depressive disorder (MDD) treatment response in clinical use. Such biomarkers could allow for individualized treatment selection, reducing time spent on ineffective treatments and the burden of MDD. In search of such a biomarker, multisite pretreatment and early-treatment (1 week into treatment) structural magnetic resonance (MR) images were acquired from 184 patients with MDD randomized to an 8-week trial of the selective serotonin reuptake inhibitor (SSRI) sertraline or placebo. This study represents a large, multisite, placebo-controlled effort to examine the association between pretreatment differences or early-treatment changes in cortical thickness and treatment-specific outcomes. For standardization, a novel, robust site harmonization procedure was applied to structural measures in a priori regions (rostral and caudal anterior cingulate, lateral orbitofrontal, rostral middle frontal, and hippocampus), chosen based on previously published reports. Pretreatment cortical thickness or volume did not significantly associate with SSRI response. Thickening of the rostral anterior cingulate cortex in the first week of treatment was associated with better 8-week responses to SSRI (p = 0.010). These findings indicate that frontal lobe structural alterations in the first week of treatment may be associated with long-term treatment efficacy. While these associational findings may help to elucidate the specific neural targets of SSRIs, the predictive accuracy of pretreatment or early-treatment structural alterations in classifying treatment remitters from nonremitters was limited to 63.9{\%}. Therefore, in this large sample of adults with MDD, structural MR imaging measures were not found to be clinically translatable biomarkers of treatment response to SSRI or placebo.",
author = "Bartlett, {Elizabeth A.} and Christine DeLorenzo and Priya Sharma and Jie Yang and Mengru Zhang and Eva Petkova and Myrna Weissman and McGrath, {Patrick J.} and Maurizio Fava and Ogden, {R. Todd} and Kurian, {Benji T.} and Ashley Malchow and Cooper, {Crystal M.} and Trombello, {Joseph M.} and Melvin McInnis and Phillip Adams and Oquendo, {Maria A.} and Pizzagalli, {Diego A.} and Madhukar Trivedi and Parsey, {Ramin V.}",
year = "2018",
month = "6",
day = "19",
doi = "10.1038/s41386-018-0122-9",
language = "English (US)",
pages = "1--10",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Pretreatment and early-treatment cortical thickness is associated with SSRI treatment response in major depressive disorder

AU - Bartlett, Elizabeth A.

AU - DeLorenzo, Christine

AU - Sharma, Priya

AU - Yang, Jie

AU - Zhang, Mengru

AU - Petkova, Eva

AU - Weissman, Myrna

AU - McGrath, Patrick J.

AU - Fava, Maurizio

AU - Ogden, R. Todd

AU - Kurian, Benji T.

AU - Malchow, Ashley

AU - Cooper, Crystal M.

AU - Trombello, Joseph M.

AU - McInnis, Melvin

AU - Adams, Phillip

AU - Oquendo, Maria A.

AU - Pizzagalli, Diego A.

AU - Trivedi, Madhukar

AU - Parsey, Ramin V.

PY - 2018/6/19

Y1 - 2018/6/19

N2 - To date, there are no biomarkers for major depressive disorder (MDD) treatment response in clinical use. Such biomarkers could allow for individualized treatment selection, reducing time spent on ineffective treatments and the burden of MDD. In search of such a biomarker, multisite pretreatment and early-treatment (1 week into treatment) structural magnetic resonance (MR) images were acquired from 184 patients with MDD randomized to an 8-week trial of the selective serotonin reuptake inhibitor (SSRI) sertraline or placebo. This study represents a large, multisite, placebo-controlled effort to examine the association between pretreatment differences or early-treatment changes in cortical thickness and treatment-specific outcomes. For standardization, a novel, robust site harmonization procedure was applied to structural measures in a priori regions (rostral and caudal anterior cingulate, lateral orbitofrontal, rostral middle frontal, and hippocampus), chosen based on previously published reports. Pretreatment cortical thickness or volume did not significantly associate with SSRI response. Thickening of the rostral anterior cingulate cortex in the first week of treatment was associated with better 8-week responses to SSRI (p = 0.010). These findings indicate that frontal lobe structural alterations in the first week of treatment may be associated with long-term treatment efficacy. While these associational findings may help to elucidate the specific neural targets of SSRIs, the predictive accuracy of pretreatment or early-treatment structural alterations in classifying treatment remitters from nonremitters was limited to 63.9%. Therefore, in this large sample of adults with MDD, structural MR imaging measures were not found to be clinically translatable biomarkers of treatment response to SSRI or placebo.

AB - To date, there are no biomarkers for major depressive disorder (MDD) treatment response in clinical use. Such biomarkers could allow for individualized treatment selection, reducing time spent on ineffective treatments and the burden of MDD. In search of such a biomarker, multisite pretreatment and early-treatment (1 week into treatment) structural magnetic resonance (MR) images were acquired from 184 patients with MDD randomized to an 8-week trial of the selective serotonin reuptake inhibitor (SSRI) sertraline or placebo. This study represents a large, multisite, placebo-controlled effort to examine the association between pretreatment differences or early-treatment changes in cortical thickness and treatment-specific outcomes. For standardization, a novel, robust site harmonization procedure was applied to structural measures in a priori regions (rostral and caudal anterior cingulate, lateral orbitofrontal, rostral middle frontal, and hippocampus), chosen based on previously published reports. Pretreatment cortical thickness or volume did not significantly associate with SSRI response. Thickening of the rostral anterior cingulate cortex in the first week of treatment was associated with better 8-week responses to SSRI (p = 0.010). These findings indicate that frontal lobe structural alterations in the first week of treatment may be associated with long-term treatment efficacy. While these associational findings may help to elucidate the specific neural targets of SSRIs, the predictive accuracy of pretreatment or early-treatment structural alterations in classifying treatment remitters from nonremitters was limited to 63.9%. Therefore, in this large sample of adults with MDD, structural MR imaging measures were not found to be clinically translatable biomarkers of treatment response to SSRI or placebo.

UR - http://www.scopus.com/inward/record.url?scp=85049127408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049127408&partnerID=8YFLogxK

U2 - 10.1038/s41386-018-0122-9

DO - 10.1038/s41386-018-0122-9

M3 - Article

SP - 1

EP - 10

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

ER -